Abstract
There currently exists limited and conflicting clinical data on the use of statins amongst COVID-19 patients. This study aimed to compare hospitalized patients with COVID-19 who did and did not receive statins in terms of clinical outcomes. Using a population-based retrospective cohort from South Korea’s nationwide healthcare database (n=4,349), we analyzed the association between prior statin use and a composite endpoint of all-cause death, ICU admission, mechanical ventilation, and cardiovascular outcomes. While the primary analysis showed no significant difference in outcomes for the general population (IPTW OR 0.82; 95% CI: 0.60–1.11), a significant protective effect was observed in patients with hypertension (IPTW OR 0.40; 95% CI: 0.23–0.69). These findings suggest that statins are safe for COVID-19 patients and may offer specific benefits to those with underlying hypertension.
Introduction
Early in the COVID-19 pandemic, the medical community faced uncertainty regarding the impact of common medications on disease severity. Statins, widely prescribed for hyperlipidemia, were a particular subject of debate. On one hand, their anti-inflammatory and immunomodulatory properties suggested a potential to dampen the "cytokine storm" associated with severe COVID-19. On the other hand, concerns were raised that statins might upregulate ACE2—the receptor used by SARS-CoV-2 for cell entry—potentially exacerbating the infection.
Given the lack of consensus, clinical guidelines generally recommended continuing statin therapy in patients already receiving it. This study sought to provide real-world evidence from a large national cohort to clarify whether pre-existing statin use influences COVID-19 outcomes.
Methods
Data Sources and Study Population
The researchers utilized two primary nationwide databases from South Korea: the Health Insurance Review and Assessment Service (HIRA), which covers approximately 98% of the population, and the Korean Disease Control and Prevention Agency (KDCA), which provided confirmed COVID-19 test results and mortality data.
The study identified 4,349 patients aged 40 years or older who were hospitalized with COVID-19 as of May 15, 2020. "Statin users" (n=1,115) were defined as individuals with inpatient or outpatient prescriptions for statins within the 240 days prior to hospitalization. "Non-users" (n=3,234) had no such records during that period.
Statistical Analysis
To account for the inherent differences between statin users (who were generally older and had more comorbidities) and non-users, the study employed Inverse Probability of Treatment Weighting (IPTW). This technique uses propensity scores to balance the two groups across 20 different comorbidities and 12 co-medications, effectively creating a balanced "pseudo-population" for comparison. The primary outcome was a composite endpoint including all-cause death, ICU admission, mechanical ventilation, and major cardiovascular events (MI, TIA, or stroke).
Results
Primary Outcomes
In the IPTW-adjusted analysis, statin use was not associated with an increased risk of the primary composite outcome. The adjusted Odds Ratio (OR) was 0.82 (95% CI: 0.60–1.11). While this indicates a trend toward protection, it did not reach statistical significance for the general cohort. However, this "neutral" result is clinically significant as it confirms that prior statin use does not worsen COVID-19 severity.
Subgroup Analysis: The Hypertension Effect
A striking finding emerged during subgroup analysis. For patients with a history of hypertension, statin use was associated with a significant reduction in adverse outcomes, with an OR of 0.40 (95% CI: 0.23–0.69). The p-value for interaction (0.0087) confirmed that hypertension significantly modified the effect of statins on COVID-19 outcomes.
Sensitivity Analyses
When the researchers applied alternative statistical models, such as Propensity Score matching or SMR weighting, the results frequently shifted toward a more pronounced protective effect for all-cause death across the entire cohort. This suggests that the primary IPTW model may have been a conservative estimate of the potential benefits of statins.
Discussion
The findings support the safety of statins in the context of COVID-19 and suggest a potential therapeutic benefit, particularly in hypertensive populations. Several biological mechanisms may explain these observations:
- Inflammation Modulation: Statins may stabilize the MYD88 protein, thereby reducing the inflammatory response.
- ACE2 Regulation: While the virus downregulates ACE2 (leading to vascular and lung injury), statins may counter this effect, protecting the vascular system.
- Endothelial Protection: Statins are known to improve endothelial function, which is often severely compromised in COVID-19 patients.
Limitations
The study is limited by its retrospective nature and reliance on administrative claims data. The researchers could not verify medication adherence (whether patients actually took the prescribed statins) or access granular clinical data such as BMI, actual blood pressure readings, or LDL cholesterol levels. Additionally, minor cardiovascular events like TIA might be underreported in claims databases.
Conclusion
This national cohort study provides evidence that pre-existing statin use is not detrimental to COVID-19 patients and may significantly improve outcomes for those with hypertension. Given that statins are widely available, inexpensive, and have a well-established safety profile, they warrant further investigation in prospective clinical trials as a potential tool in the management of COVID-19.
Summary updated